Description

2H-1,4-Benzodiazepin-2-One, 5-(2-Chlorophenyl)-1,3-Dihydro-7-(Iodo-125 I)- CAS NO 106077-19-4 is a specialized, radiolabeled benzodiazepine derivative, a critical tool for advanced research and diagnostic development. Its core value lies in the incorporation of the iodine-125 radioisotope, enabling highly sensitive detection and quantification in biological systems. This compound is essential for researchers and developers in the pharmaceutical and biotechnology sectors, particularly those focused on neuroscience, receptor binding studies, and the creation of novel radiopharmaceuticals for diagnostic imaging.

Application

• Receptor Binding Assays: Used as a high-specific-activity radioligand for studying benzodiazepine receptor sites (e.g., GABAA receptors) in the central nervous system.
• Drug Discovery & Development: Serves as a key tracer in competitive binding studies to screen and characterize new therapeutic candidates targeting benzodiazepine pathways.
• Metabolic & Pharmacokinetic Studies: Enables the detailed tracking of drug distribution, absorption, and excretion in preclinical research models.
• Diagnostic Probe Development: Acts as a precursor or model compound for developing iodine-125 labeled diagnostic agents for SPECT imaging applications.
• Biochemical Research: Facilitates the study of enzyme interactions, protein binding, and other molecular mechanisms where benzodiazepine structures are involved.
• Quality Control (Radiopharmaceuticals): Employed as a reference standard in the manufacturing and quality assurance of related radioactive diagnostic products.

Basic Information

Product Name	2H-1,4-Benzodiazepin-2-One, 5-(2-Chlorophenyl)-1,3-Dihydro-7-(Iodo-125 I)-
CAS No.	106077-19-4
Molecular Formula	C15H10Cl125IN2O
Molecular Weight	~424.6 (for 125I isotope)
Synonyms	7-Iodo-125I-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; [125I]Iomazenil (partial structure analog); Ro 16-0154 Iodine-125; 125I-labeled Benzodiazepine Derivative; 5-(2-Chlorophenyl)-7-iodo-125I-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Iodine-125 Iomazenil; Radiolabeled Flumazenil analog
EINECS	Contact for details

Quality Control

Every batch of this radiolabeled compound is produced and analyzed under strict quality systems. Radiochemical purity (RCP) and specific activity are critically assessed using validated HPLC and gamma counting methods to ensure performance in sensitive assays. A comprehensive Certificate of Analysis (COA) is provided with each shipment, detailing purity, radioactivity concentration, and analytical results. Production adheres to GMP-like guidelines suitable for research and non-clinical development applications.

Storage

Preserve in the original lead-shielded container, tightly sealed, and stored at -20°C or below. This product is strictly light-sensitive (protect from all light exposure). Store in a designated, secure area for radioactive materials, in compliance with all local and international regulations for handling radiochemicals.

Specification

Item	Specification
Appearance	White to off-white solid (in solution as provided)
Identification (HPLC)	Retention time corresponds to reference standard
Radiochemical Purity (HPLC)	≥ 95%
Specific Activity	Contact for details (typically >2000 Ci/mmol)
Radioactivity Concentration	As specified on COA
Solvent (if supplied in solution)	Ethanol or other specified solvent

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.